Renalytix Plc (RENXF) Financials
Newest figures come from the 10-Q for Q1 FY2025, filed Nov 19, 2024. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RENXF SEC filings page.
Renalytix Plc (RENXF) reported $2.4M in revenue over the twelve months to Sep 30, 2024, down 18.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
RENXF remains a development-stage business where research spending and financing, rather than sales, drive the operating model.
In FY2024, R&D intensity was$9.3M against$2.3M of revenue, while operating cash flow was-$30.1M versus a net loss of-$33.5M ; that narrow gap indicates the reported loss is largely tied to cash-consuming operations rather than mainly noncash charges. The company therefore has not yet converted development spending into a self-funding commercial engine.
Commercial traction has not produced a scalable margin structure: revenue fell from
Liquidity and solvency have both tightened: FY2024 current ratio was 0.5x, meaning current assets did not cover current liabilities. Liabilities of
Financial Health Signals
Renalytix Plc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Renalytix Plc passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
Renalytix Plc reported a net loss of $33.5M while operations used $30.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Renalytix Plc generated $522K in revenue in Q1 2025. This represents an increase of 13.7% from the same quarter a year earlier. Against the prior quarter it is down 10.9%.
Renalytix Plc's EBITDA was -$4.0M in Q1 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 54.0% from the same quarter a year earlier. Against the prior quarter it is up 25.4%.
Renalytix Plc reported -$4.7M in net income in Q1 2025. This represents an increase of 53.4% from the same quarter a year earlier. Against the prior quarter it is up 33.2%.
Cash & Balance Sheet
Renalytix Plc held $909K in cash as of Q1 2025; long-term debt is not reported for that period.
Not reported for Q1 2025.
Not reported for Q1 2025.
Margins & Returns
Renalytix Plc's gross margin was 19.2% in Q1 2025, indicating the percentage of revenue retained after direct costs. This is up 28.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 13.0 percentage points.
Not shown for Q1 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q1 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q1 2025.
Capital Allocation
Renalytix Plc invested $921K in research and development in Q1 2025. This represents a decrease of 67.0% from the same quarter a year earlier. Against the prior quarter it is down 13.3%.
Not reported for Q1 2025.
Not reported for Q1 2025.
RENXF Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $522K+13.7% | $586K+13.1% | $535K-26.1% | $709K-40.5% | $459K-52.6% | $518K-37.7% | $724K-10.8% | $1.2M+41.1% |
| Cost of Revenue | $422K-15.9% | $550K-18.3% | $601K-0.3% | $480K-32.5% | $502K-27.9% | $673K-2.7% | $603K-12.0% | $711K+44.5% |
| Gross Profit | $100K+332.6% | $36K+123.2% | -$66K-154.5% | $229K-52.4% | -$43K-115.8% | -$155K-211.5% | $121K-4.7% | $481K+36.3% |
| R&D Expenses | $921K-67.0% | $1.1M-67.5% | $2.2M-43.8% | $3.2M-3.0% | $2.8M-25.8% | $3.3M+24.5% | $3.9M+1.4% | $3.3M-19.5% |
| SG&A Expenses | $3.3M-46.0% | $4.5M-30.9% | $3.9M-45.7% | $5.3M-21.6% | $6.1M-26.6% | $6.5M-38.1% | $7.1M-34.4% | $6.8M-32.4% |
| Operating Income | -$4.1M+54.0% | -$5.5M+44.4% | -$6.6M+40.0% | -$8.6M+10.4% | -$8.9M+24.2% | -$9.9M+23.9% | -$10.9M+24.9% | -$9.6M+30.0% |
| EBITDA | -$4.0M+54.0% | -$5.4M+44.6% | -$6.5M+39.6% | -$8.5M+10.5% | -$8.8M+24.4% | -$9.8M+24.3% | -$10.8M+25.1% | -$9.5M+30.2% |
| Income Tax | $2K | $0-100.0% | $0+100.0% | $4K | $0-100.0% | $2K-92.0% | -$1K | $0 |
| Net Income | -$4.7M+53.4% | -$7.1M+36.3% | -$7.7M+36.0% | -$8.5M+18.8% | -$10.2M+15.1% | -$11.1M-115.5% | -$12.1M+17.6% | -$10.4M+31.8% |
| EPS (Basic) | -$0.04+63.6% | -$0.04+63.6% | -$0.08+42.9% | -$0.09+35.7% | -$0.11+31.3% | -$0.11-83.3% | -$0.14+30.0% | -$0.14+33.3% |
| EPS (Diluted) | -$0.04 | -$0.04 | -$0.08+42.9% | -$0.09+35.7% | -$0.11+31.3% | -$0.11 | -$0.14+30.0% | -$0.14+33.3% |
| Diluted Shares (Avg) | 106M | N/A | 98M+14.1% | 97M+29.9% | 95M+26.7% | N/A | 86M+18.3% | 75M+3.6% |
Not reported in any period shown, so not listed: Interest Expense.
RENXF Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.8M-75.5% | $8.0M-74.0% | $8.8M-78.0% | $11.3M-63.2% | $19.5M-49.5% | $30.6M-38.8% | $39.8M-10.5% | $30.7M-43.6% |
| Current Assets | $2.9M-82.5% | $6.1M-77.2% | $6.3M-82.3% | $8.3M-69.0% | $16.5M-52.2% | $26.9M-39.9% | $35.7M-4.2% | $26.6M-40.1% |
| Cash & Equivalents | $909K-93.5% | $4.7M-81.0% | $4.7M-85.8% | $5.6M-76.4% | $13.9M-55.2% | $24.7M-40.3% | $33.0M+2.1% | $23.8M-40.4% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Receivable | $902K-11.0% | $722K-7.0% | $554K-25.8% | $1.4M+67.1% | $1.0M-17.1% | $776K-13.9% | $747K-26.0% | $820K-0.4% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $16.1M-23.4% | $15.8M-33.1% | $19.9M-8.4% | $19.2M-11.7% | $21.0M+5.8% | $23.7M+21.6% | $21.7M+44.2% | $21.8M+154.5% |
| Current Liabilities | $12.0M-20.8% | $11.5M-28.8% | $15.0M+2.1% | $13.9M-2.6% | $15.2M+13.8% | $16.1M+37.0% | $14.7M-2.3% | $14.3M+67.3% |
| Non-Current Liabilities | $4.1M-30.0% | $4.3M-42.5% | $4.9M-30.3% | $5.3M-29.1% | $5.9M-10.4% | $7.5M-2.0% | $7.0M+50050.0% | $7.5M+49820.0% |
| Total Equity | -$11.3M-659.2% | -$7.9M-212.7% | -$11.1M-161.4% | -$8.0M-189.5% | -$1.5M-107.9% | $7.0M-77.2% | $18.1M-38.5% | $8.9M-80.6% |
| Retained Earnings | -$216.5M-14.9% | -$211.8M-18.8% | -$204.7M-22.4% | -$197.0M-27.0% | -$188.5M-30.3% | -$178.3M-34.4% | -$167.2M-31.1% | -$155.1M-37.4% |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
RENXF Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.8M+59.6% | -$7.8M+9.3% | -$4.9M+51.9% | -$7.9M+3.8% | -$9.5M-33.5% | -$8.6M+39.1% | -$10.1M-43.8% | -$8.2M+42.2% |
| Depreciation & Amortization | $60K-52.8% | $60K-50.0% | $20K-80.0% | $100K0.0% | $127K-2.3% | $120K-11.1% | $100K0.0% | $100K0.0% |
| Stock-Based Compensation | $254K-51.4% | N/A | $385K-50.0% | $385K-52.8% | $523K-31.8% | N/A | $770K-16.6% | $815K-10.7% |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $0-100.0% | $0-100.0% |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | -$8.6M+39.3% | -$10.1M-37.4% | -$8.2M+42.5% |
| Investing Cash Flow | $23K | -$1K-101.7% | -$3K-160.0% | $0+100.0% | $0 | $59K-1.7% | $5K+101.5% | -$64K+51.1% |
| Financing Cash Flow | $0+100.0% | $7.8M+8048.0% | $4.0M-77.6% | -$507K+13.8% | -$1.1M-12.8% | -$98K-100.4% | $18.0M | -$588K-629.7% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
RENXF Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 19.2%+28.5pp | 6.1%+36.1pp | -12.3%-29.0pp | 32.3%-8.1pp | -9.4%-37.5pp | -29.9%-46.7pp | 16.7%+1.1pp | 40.4%-1.4pp |
| Operating Margin | -784.1% | -942.8% | -1224.9% | -1218.8% | -1936.6% | -1917.8% | -1507.9% | -809.4% |
| Net Margin | -905.7% | -1207.2% | -1447.3% | -1196.8% | -2212.2% | -2143.6% | -1672.1% | -876.2% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | -159.4%-142.5pp | -66.9%-16.9pp | -117.5%-84.1pp |
| Return on Assets | -98.6%-46.6pp | -88.7%-52.5pp | -88.3%-57.9pp | -75.3%-41.2pp | -52.0%-21.1pp | -36.3%-26.0pp | -30.4%+2.6pp | -34.1%-5.9pp |
| Current Ratio | 0.24-0.8x | 0.53-1.1x | 0.42-2.0x | 0.59-1.3x | 1.09-1.5x | 1.67-2.1x | 2.430.0x | 1.86-3.3x |
| Debt-to-Equity | N/A | N/A | N/A | N/A | N/A | 3.40+2.8x | 1.20+0.7x | 2.45+2.3x |
| Asset Turnover | 0.11+0.1x | 0.07+0.1x | 0.060.0x | 0.060.0x | 0.020.0x | 0.020.0x | 0.020.0x | 0.040.0x |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | -1666.6% | -1395.2% | -690.6% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$7.9M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.53), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Where Renalytix Plc Ranks
Frequently Asked Questions
What is Renalytix Plc's annual revenue?
Renalytix Plc (RENXF) reported $2.3M in total revenue for fiscal year 2024. This represents a -32.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Renalytix Plc's revenue growing?
Renalytix Plc (RENXF) revenue declined by 32.7% year-over-year, from $3.4M to $2.3M in fiscal year 2024.
Is Renalytix Plc profitable?
No, Renalytix Plc (RENXF) reported a net income of -$33.5M in fiscal year 2024.
What is Renalytix Plc's EBITDA?
Renalytix Plc (RENXF) had EBITDA of -$29.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Renalytix Plc's gross margin?
Renalytix Plc (RENXF) had a gross margin of 6.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Renalytix Plc's operating cash flow?
Renalytix Plc (RENXF) recorded an outflow of $30.1M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are Renalytix Plc's total assets?
Renalytix Plc (RENXF) had $8.0M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Renalytix Plc spend on research and development?
Renalytix Plc (RENXF) invested $9.3M in research and development during fiscal year 2024.
What is Renalytix Plc's current ratio?
Renalytix Plc (RENXF) had a current ratio of 0.53 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Renalytix Plc's return on assets (ROA)?
Renalytix Plc (RENXF) had a return on assets of -419.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
Why is Renalytix Plc's debt-to-equity ratio negative or not reported?
Renalytix Plc (RENXF) has negative shareholder equity of -$7.9M as of fiscal year 2024, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Renalytix Plc's Piotroski F-Score?
Renalytix Plc (RENXF) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Renalytix Plc's earnings high quality?
Renalytix Plc (RENXF) reported a net loss of $33.5M while operations used $30.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.